Hypertension is the medical term for high blood pressure. Persistent high blood pressure can lead to increased strain to the heart and arteries that can eventually cause organ damage.
To classify the blood pressure, it must be based on ≥2 properly measured, seated blood pressure readings on each of ≥2 office visits.
Patients who have a blood pressure reading of 130 SBP or ≥80 DBP or both can be diagnosed as hypertensive patients.
Goals of therapy are to manage hypertension that can maintain the patient's normal blood pressure and identify and treat all reversible risk factors.

Principles of Therapy

Treatment Goals

  • To manage hypertension
    • To achieve and maintain BP goal based on age, presence/absence of comorbidities (eg DM and chronic kidney disease)
  • To prevent complications through identification and management of all other identified risk factors for CVD (DM or glucose intolerance, lipid disorders, obesity, smoking)
    • Identification and treatment of all reversible risk factors
    • Management of concomitant disorders (eg DM, established CV or renal disease)

Target BP1

  • Reduce BP to <140/90 in all patients
  • If therapy is well tolerated, a treated BP goal of ≤130/80 is recommended for:
    • Patients with clinical CVD or ≥10% ASCVD risk in 10 years
    • Patients without clinical CVD and <10% ASCVD risk in 10 years
    • Patients with comorbidities such as DM, CKD, heart failure, stable ischemic heart disease, peripheral arterial disease and for secondary stroke prevention  
  • An SBP goal of 130-139 mmHg is recommended for patients ≥65 years old receiving antihypertensive therapy
  • An SBP goal of 120-129 mmHg in most patients <65 years old receiving antihypertensive therapy is recommended  
  • A DBP goal of <80 mmHg should be considered in all patients regardless of risk level and comorbidities

1Recommendations for BP target goals may vary between countries. Please refer to available guidelines from local health authorities.

General Principles

Initiating Treatment

  • Decision to initiate therapy is based on the untreated BP level and presence of TOD or concomitant disorders
  • Primary prevention is recommended for patients:  
    • Without prior history of CVD but with a ≥10% estimated 10-year ASCVD risk and SBP ≥130 mmHg or DBP ≥80 mmHg
    • Without prior history of CVD but with a <10% estimated 10-year ASCVD risk and SBP  ≥140 mmHg or DBP ≥90 mmHg
  • Secondary prevention of recurrent CVD events is recommended in patients with clinical CVD and SBP ≥130 mmHg or DBP ≥80 mmHg  
  • Pharmacological therapy is recommended in fit patients >80 years old with an SBP of ≥160 mmHg and have not received BP treatment provided therapy is well tolerated 
  • Implement lifestyle changes throughout management
    • A defined time period of lifestyle changes may be considered in patients with medication intolerance and <10% 10-year ASCVD risk   
    • Medication is started together with lifestyle changes in patients  elevations in SBP of >20 mmHg or DBP of >10 mmHg above BP goal; and in fit patients 65-80 years old with SBP 140-159 mmHg if therapy is well tolerated  
    • In patients with BP ≥140/90 mmHg at low-moderate risk and no target organ damage, pharmacological therapy can be started if still hypertensive despite lifestyle changes for 3-6 months   
  • Start drug treatment promptly in all patients for whom it is necessary to achieve a more rapid control of BP

Treatment Regimen

  • Assessment of BP and adjustment of treatment regimen is continuous until BP goal is reached 
  • Most patients will need >1 drug to achieve BP control, though it is reasonable to start with a single antihypertensive agent in low-risk patients with baseline BP that is close to recommended goal, or frail or old patients who need gentle BP reduction
  • Different strategies may be considered based on individual circumstances, preferences of physician and patient:
    • Start with 2 1st-line agents from separate drug classes, either separately or in a fixed-dose or single-pill combination
    • Maximize first medication before adding a second drug
      • If BP goal is not reached within one month of treatment, increase the dose of the drug
    • Add a 2nd drug prior to reaching the maximum dose of the 1st drug
      • Add new drugs at approximately 2- to 3-week intervals, but may also depend on the physician’s judgment
      • If goal BP cannot be achieved using 2 drugs, add and titrate a 3rd drug
  • Initial doses of drugs should be at least half the maximum dose so only one dose adjustment is needed to be done thereafter
  • In general, it is expected to reach the effective regimen within 6-8 weeks, regardless whether 1, 2 or 3 drugs were employed
    • Consider stepping down therapy if patient's BP remains controlled after 1-2 years of therapy and is without symptoms related to hypertension or TOD
  • Referral to a hypertension specialist may be necessary when goal BP cannot be achieved despite above strategies or when managing patients for whom additional consultation is warranted

Choice of Antihypertensive Agents

  • Choice is influenced by the following factors:
    • Patient’s age, ethnicity/race
    • Patient’s previous history with antihypertensive medications
      • Monitor for adverse reactions to avoid patient’s noncompliance to medications
    • Presence of other medical conditions
      • Eg coronary diseases, DM, renal disease, pregnancy, thiazide
    • Possibility of drug interactions with drugs used for other conditions
    • Patient preference
    • Cost (affordability) and availability of the drugs
      • Cost consideration should not predominate efficacy and tolerability
  • Long-acting drugs or preparations providing 24-hour efficacy that can be given once daily are preferred
    • Improves compliance and minimizes BP variability
    • Once-daily drugs can be taken at any time during the day (either morning or evening)
  • When >1 drug is needed, the use of a combination product (2 appropriate medications in a single tablet) can simplify the regimen and improve adherence of patients


ACE Inhibitors (ACEI)

  • Block the conversion of angiotensin I to angiotensin II by inhibiting angiotensin-converting enzyme (ACE)
  • ACE inhibitors are suitable for initiation and maintenance of therapy
  • Have established clinical outcome benefits in patients with chronic heart failure (CHF) and post myocardial infarction (MI) patients with reduced LV ejection fraction; also effective in reducing LV hypertrophy and preserving kidney function
  • Are well-tolerated; most common side effect is dry cough (most common in women and among Asian and African patients) related to effects of bradykinin or prostaglandin metabolism
  • There is a risk of hypotension when starting treatment with ACE inhibitors in patients who are already on diuretics, or are on low-salt diet or are dehydrated
    • For patients on diuretics, skipping a dose prior to starting ACE inhibitor may help prevent this sudden drop in BP
  • Should not be combined with angiotensin receptor blockers or direct renin inhibitors
  • Drug effects do not seem to have dose-dependent effects, except for hyperkalemia which may occur more frequently with high doses
    • Allows patient to initiate treatment using medium or even approved high doses


  • Reduce BP by blocking arterial alpha-adrenergic receptors, in effect, preventing the vasoconstrictor actions of these receptors
  • Less widely used as first-line agents due to limited evidence for their clinical outcome benefits
  • Are useful in treating resistant hypertension when used in combination with other agents such as beta-blockers, diuretics and ACE inhibitors
  • Are beneficial part of treatment regimens for older hypertensive men with benign prostatic hypertrophy
  • Have favorable effects on blood glucose and lipid levels

Angiotensin II Antagonists (also called Angiotensin Receptor Blockers or ARBs)

  • Act by blocking the action of angiotensin II on its AT1 receptors, preventing the vasoconstrictor effects of this receptor
  • Provide the same CV and renal benefits as ACE inhibitors
  • Should not be combined with ACE inhibitors or direct renin inhibitors
  • Are well tolerated; do not cause cough and only rarely cause angioedema
  • Drug effects do not appear to have dose-dependent effects
    • Allows patient to start with medium or even maximum approved doses
  • For patients on diuretics, skipping a dose of the diuretic prior to starting ARBs may help prevent sudden drop in BP
  • Can be used to prevent recurrence of atrial fibrillation


  • Beta-blockers have a long history in the treatment of hypertension
  • For patients without conditions warranting beta-blockade, beta-blockers should not be used as initial therapy
  • Drug of choice in patients with history of MI and heart failure
    • Useful in patients with effort angina, tachyarrhythmia and have been shown to reduce CV morbidity and mortality in post-MI patients and risk of exacerbations and mortality in patients with chronic obstructive lung disease
  • Studies show that Celiprolol, Carvedilol and Nebivolol (3rd generation of beta-blockers) can reduce central pulse pressure and aortic stiffness as compared to Metoprolol and Atenolol (2nd generation of beta-blockers); Nebivolol has less effects on insulin sensitivity than Metoprolol
  • Act as competitive antagonists of the effects of catecholamines at beta-adrenergic receptor sites
    • Beta2-blockade can increase bronchial resistance and inhibition of catecholamine-induced glucose metabolism
    • Beta-blockers have different affinities for beta1- or beta2-blockade but as doses are increased, activity of beta2 receptors can become apparent in beta1-selective inhibitors
  • Combination with thiazide diuretic is shown to have dysmetabolic effect and increased incidence of new onset diabetes among patients and is therefore, not recommended in patients at risk for diabetes

Calcium (Ca) Antagonists

  • Act by blocking the inward flow of calcium ions through the L channels of arterial smooth muscle cells
  • Ca antagonists are powerful antihypertensive agents, especially when given in combination with ACE inhibitors or with ARBs
  • Main side effect is peripheral edema, most especially at high doses; though a clinical rather than a laboratory approach most often is enough to eliminate a renal or hepatic etiology for the edema
    • Reduced by combining with ACE inhibitors or ARBs

Dihydropyridine Ca Antagonists

  • Eg Amlodipine, Cilnidipine, Felodipine, Isradipine, Manidipine, Nicardipine, Nifedipine, Nisoldipine
  • Usually used for their antihypertensive and anti-anginal effects
  • Dihydropyridines have shown beneficial effects on stroke and CV outcomes in hypertension trials
  • Dihydropyridines (but not nondihydropyridines) can be safely combined with beta-blockers
  • Have greater selectivity for vascular smooth muscle than for myocardium and their main effect is vascular relaxation
    • They have little or no effect at the SA or AV nodes and negative inotropic activity is not typical at therapeutic doses

Benzothiazepine and Phenylalkylamine Ca Antagonists (Non-dihydropyridine Ca Antagonists)

  • Eg Diltiazem, Verapamil
  • Typically used for their antiarrhythmic, anti-anginal and antihypertensive properties
  • Tend to have less selective vasodilatory activity than dihydropyridine Ca antagonists
    • They have direct effect on myocardium causing depression of SA and AV conduction
  • Nondihydropyridines are preferred in patients with fast heart rates and rate control for atrial fibrillation patients who cannot tolerate beta-blockers
  • A randomized controlled trial revealed that Verapamil + Trandolapril was as clinically effective as Atenolol + Hydrochlorothiazide in hypertensive patients with coronary artery disease
  • Preferred in patients with proteinuria due to the additional antiproteinuric effect in Diltiazem and Verapamil

Direct Renin Inhibitors

  • Eg Aliskiren
  • Found to be as effective as angiotensin receptor blockers (ARB) and ACE inhibitors without dose-related increase in side effects in the elderly; combination with ACE inhibitor or ARB is not recommended
  • Current available data show that Aliskiren:
    • As monotherapy, lowers systolic BP and diastolic BP in younger and elderly hypertensive patients
    • Has a greater BP lowering effect when used in combination with a thiazide diuretic, a renin angiotensin blocker or a calcium channel blocker
    • Prolonged use in combination treatment can have a favorable effect on asymptomatic organ damage
  • Appears well tolerated among patients >75 years of age, including those with renal disease (with estimated GFR ≥30 mL/min/1.73 m2)
  • Main side effect is mild diarrhea


  • Use of diuretics has been well-established in the treatment of hypertension and diuretics are suitable for initiation and maintenance of therapy
    • When used in combination, diuretics may enhance the efficacy of concurrently used antihypertensive drug
    • Reduce the risk of fatal and nonfatal stroke and have been shown to reduce CV morbidity and mortality and all-cause mortality
    • Drug of choice in the elderly with no comorbid conditions
  • Combination treatment with potassium-sparing diuretics (eg Amiloride, Triamterene), mineralocorticoid antagonists (eg Spironolactone, Eplerenone), and epithelial sodium transport channel antagonists with other agents are useful in treating hypertension by reducing vascular stiffness and SBP

Aldosterone Antagonists

  • Eg Spironolactone, Eplerenone
  • Preferred therapeutic agents for resistant hypertension and primary aldosteronism 
  • Have recently been part of standard treatment of heart failure
  • Can be effective in lowering BP when added to standard 3-drug regimens (ACEI or ARB/Ca antagonist/diuretic) in treatment-resistant hypertension

Loop Diuretics

  • Eg Furosemide, Torasemide, Bumetanide
  • Preferred agents in patients with symptomatic heart failure
  • Loop diuretics are preferred over thiazide diuretics in patients with renal insufficiency

Thiazide and Thiazide-like Diuretics

  • Eg Chlorthalidone, Hydrochlorothiazide, Indapamide, Metolazone
  • Act by increasing elimination of sodium by kidneys and may have some vasodilator effects
  • Inexpensive and are the most widely used of the antihypertensive agents
  • With proven clinical outcome benefits in reducing strokes and major CV events
    • Chlorthalidone has a longer duration of action and proven reduction of CVD risk
  • Main side effects (metabolic, such as hypokalemia, hyponatremia, hyperuricemia, hyperglycemia) are reduced by lowering the doses or combining them with ACE inhibitors
  • Used in combination with potassium-sparing diuretic to prevent thiazide-induced hypokalemia
  • Most effective in BP reduction when combined with ACE inhibitors or ARBs
    • Also effective when combined with calcium channel blockers

Other Antihypertensives

Centrally-Acting Agents

  • Eg Clonidine, Methyldopa
  • More often used nowadays as part of multiple drug combinations
  • Act by reducing sympathetic outflow from the central nervous system
  • Methyldopa may be considered in resistant hypertension in combination with other antihypertensive agents
    • Safe to use in pregnancy

Direct Vasodilators

  • Eg Hydralazine, Minoxidil 
  • Are most effective in reducing BP when combined with diuretics and beta-blockers or sympatholytic agents
  • Usually used only as 4th line or later additions to treatment regimens


Preferred Antihypertensives

Angina pectoris

  • Beta-blocker
  • Ca antagonist

Asymptomatic atherosclerosis

  • ACE inhibitor
  • Ca antagonist

Atrial fibrillation


  • Angiotensin II antagonist
  • ACE inhibitor
  • Beta-blocker
  • Aldosterone antagonist


  • Beta-blocker
  • Ca antagonist (Non-dihydropyridine)

Diabetes mellitus

Combination of ≥2 drugs are typically needed to reach target BP

  • ACE inhibitor or Angiotensin II antagonist
  • Beta-blocker
  • Thiazide diuretic
  • Ca antagonist

Heart failure

Asymptomatic patients with ventricular dysfunction:

  • ACE inhibitor

Symptomatic ventricular dysfunction or end-stage heart disease:

  • ACE inhibitor
  • Angiotensin II antagonist
  • Angiotensin receptor-neprilysin inhibitor
  • Aldosterone antagonist
  • Beta-blocker
  • Thiazide diuretic

Isolated systolic hypertension (ISH) (elderly)

  • Diuretics
  • Direct renin inhibitor
  • Ca antagonist

LV hypertrophy

  • Angiotensin II antagonist
  • ACE inhibitor
  • Ca antagonist

Metabolic syndrome

  • ACE inhibitor
  • Angiotensin II antagonist
  • Ca antagonist


  • ACE inhibitor
  • Angiotensin II antagonist
  • Direct renin inhibitor

Peripheral arterial disease

  • Ca antagonist
  • Beta-blocker (if with arterial hypertension)
  • ACE inhibitor

Post MI

  • ACE inhibitor
  • Aldosterone antagonist
  • Angiotensin II antagonist
  • Beta-blocker

Post stroke

  • Any BP lowering agent
  • Ca antagonist

Proteinuria/End-stage renal disease

  • ACE inhibitor
  • Loop diuretics
  • Angiotensin II antagonist

Effective Antihypertensive Combinations

Combination therapy can be initiated in hypertension stage 2 and above or hypertension within those at higher risk for CVD. In 15-20% of hypertensive patients, BP control cannot be achieved with a two-drug combination; in this case, a three-drug combination may be used, preferably in a fixed-dose or single-pill combination

  • ACE inhibitor or angiotensin II antagonist + Ca antagonist and/or diuretic  
  • ACE inhibitor or angiotensin II antagonist + Ca antagonist or beta-blocker  
  • Ca antagonist + beta-blocker or diuretic  
  • Beta-blocker + diuretic

Many antihypertensive combinations are available. Please see the Product Section and the latest MIMS for specific formulations and prescribing information.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
Less focus must be given on pretreatment blood pressure (BP) levels, which rarely predict future untreated BP levels or rule out capacity to benefit from BP lowering in high cardiovascular risk patients, according to recent study. Focus must be directed instead on prompt, empirical treatment to maintain lower BP for individuals with high BP or high risk.
16 Nov 2018
Atrial fibrillation appears to be the strongest determinant of stroke over 48 years of follow-up in males, a study has found.
15 Nov 2018
Psychological functioning consistently predicts symptom severity and health-related quality of life (hr-QOL) in atrial fibrillation (AF) patients with preserved left ventricular function, a recent study has found.
Audrey Abella, 16 Nov 2018
Supplementation with either omega-3 fatty acids (ie, fish oil) or vitamin D did not reduce the incidence of major cardiovascular (CV) events (ie, composite of myocardial infarction [MI], stroke, and CV death) or total invasive cancer, according to the VITAL* trial presented at AHA 2018.